This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Astellas Pharma Europe Ltd.
Reference
Nazir J, et al. Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. PharmacoEconomics-Open : 30 Jan 2017. Available from: URL: http://dx.doi.org/10.1007/s41669-017-0011-x
Rights and permissions
About this article
Cite this article
Mirabegron for OAB saves costs in the UK. PharmacoEcon Outcomes News 771, 18 (2017). https://doi.org/10.1007/s40274-017-3729-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3729-x